Liverpool have entered the race to challenge Bayern Munich for the signing of RB Leipzig striker Timo Werner, according to AZ Information. The 22-year-old has built a reputation as one of the Europe’s most sought after forwards by scoring 55 times in 96 matches for the German club. Timo’s form at club level has seen […]
Reported by Shoot 9 minutes ago.
Liverpool want to bring exciting German international to Anfield
↧
↧
GBT Appoints Dawn Svoronos to Board of Directors
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Dawn Svoronos to the company’s board of directors. Ms. Svoronos has more than 30 years of experience in the biopharmaceutical industry in the United States, Canada, Europe and Asia, including a nearly 25-year tenure at Merck & Co.“Dawn is a global biopharmaceutical leader whose addition to the board will strengthen the existing breadth of talent,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Her extensive commercial expertise will be invaluable as we continue on the trajectory of submitting a New Drug Application for voxelotor for the treatment of sickle cell disease under an accelerated approval pathway and prepare for our first commercial launch. Additionally, as we look towards voxelotor commercial opportunities outside of the U.S., Dawn’s experience will be invaluable. We look forward to Dawn’s insights and perspectives and welcome her to the board.”
“This is an exciting time to join GBT’s board given the recent clarity on the U.S. regulatory strategy for voxelotor and the positive Phase 3 HOPE Study clinical data,” said Ms. Svoronos. “I look forward to bringing my commercial experience in the biopharmaceutical industry to GBT to help the company move closer toward its goal of commercializing voxelotor, a new potentially disease-modifying therapy for the treatment of sickle cell disease.”
In 2014, while serving on the board of directors of Medivation Inc., Dawn stepped in as interim chief commercial officer for Medivation and oversaw the sales and marketing for the company’s oncology drug. Before that, she spent nearly 25 years at Merck, where she held positions of increasing seniority and leadership. Prior to her retirement from Merck in 2011, she served as President of Europe/Canada where she completed a rapid and seamless post-merger integration of the Merck and Schering-Plough organizations and subsequently led operations in 30 EU markets. Previous positions at Merck include President of Merck Canada, and vice-president of Asia Pacific where Ms. Svoronos worked extensively in Japan, mainland China and several countries in southeast Asia, building or strengthening the Merck presence in these areas. Earlier, as vice-president of global marketing for Merck’s Arthritis, Analgesics and Osteoporosis franchises, Ms. Svoronos managed the global brand positioning, market and competitive intelligence, pricing and lifecycle strategies for 10 products across these three therapeutic areas. Currently, Ms. Svoronos sits on the boards of several public companies including Endocyte and PTC Therapeutics. She received a B.A. in English and French literature from Carleton University in Ottawa, Canada.
*About Voxelotor in Sickle Cell Disease*
Voxelotor (previously called GBT440) is being developed as an oral, once-daily therapy for patients with sickle cell disease (SCD). Voxelotor works by increasing hemoglobin's affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, GBT believes voxelotor blocks polymerization and the resultant sickling of red blood cells. With the potential to improve hemolytic anemia and oxygen delivery, GBT believes that voxelotor may potentially modify the course of SCD. In recognition of the critical need for new SCD treatments, the U.S. Food and Drug Administration (FDA) has granted voxelotor Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations for the treatment of patients with SCD. The European Medicines Agency (EMA) has included voxelotor in its Priority Medicines (PRIME) program, and the European Commission (EC) has designated voxelotor as an orphan medicinal product for the treatment of patients with SCD.
GBT is currently evaluating voxelotor in the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study, a Phase 3 clinical study in patients age 12 and older with SCD. Additionally, voxelotor is being studied in the ongoing Phase 2a HOPE-KIDS 1 Study, an open-label, single- and multiple-dose study in pediatric patients (age 4 to 17) with SCD. The HOPE-KIDS 1 Study is assessing the safety, tolerability, pharmacokinetics and exploratory treatment effect of voxelotor.
*About GBT*
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing two therapies for the potential treatment of sickle cell disease, including its late-stage product candidate, voxelotor, as an oral, once-daily therapy. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
*Forward-Looking Statements *
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about GBT’s anticipated public offering, anticipated use of proceeds and other statements containing the words “anticipate,” “planned,” “believe,” “forecast,” “estimated,” “expected,” and “intend,” among others. These forward-looking statements are based on GBT’s current expectations and actual results could differ materially. Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements, including statements regarding the availability of, and sufficiency of our data to support, accelerated regulatory approval, our plans to submit an NDA for voxelotor and prepare for commercial launch, our clarity with the FDA regarding our regulatory strategy, the therapeutic potential and safety profile of voxelotor, including the potential for voxelotor to be a disease-modifying treatment for SCD, our ability to implement and complete our clinical development plans for voxelotor, our ability to engage in continued discussions with the FDA and the outcome of our discussions with the FDA, our ability to generate and report data from our ongoing and potential future studies of voxelotor (including additional data from patients enrolled in our ongoing Phase 3 HOPE Study, and data in our ongoing Phase 2a HOPE-KIDS 1 Study), regulatory review and actions relating to voxelotor, and the timing of these events, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the risks that our clinical and preclinical development activities may be delayed or terminated for a variety of reasons, that results of clinical trials may be subject to differing interpretations, that regulatory authorities may disagree with our clinical development plans or require additional studies or data to support further clinical investigation of our product candidates, that drug-related adverse events may be observed in clinical development, and that data and results may not meet regulatory requirements or otherwise be sufficient for further development, regulatory review or approval, along with those risks set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
*Contact Information: *
Myesha Lacy (investors)
GBT
650-351-4730
investor@gbt.com
Stephanie Yao (media)
GBT
650-741-7730
media@gbt.com Reported by GlobeNewswire 5 minutes ago.
“This is an exciting time to join GBT’s board given the recent clarity on the U.S. regulatory strategy for voxelotor and the positive Phase 3 HOPE Study clinical data,” said Ms. Svoronos. “I look forward to bringing my commercial experience in the biopharmaceutical industry to GBT to help the company move closer toward its goal of commercializing voxelotor, a new potentially disease-modifying therapy for the treatment of sickle cell disease.”
In 2014, while serving on the board of directors of Medivation Inc., Dawn stepped in as interim chief commercial officer for Medivation and oversaw the sales and marketing for the company’s oncology drug. Before that, she spent nearly 25 years at Merck, where she held positions of increasing seniority and leadership. Prior to her retirement from Merck in 2011, she served as President of Europe/Canada where she completed a rapid and seamless post-merger integration of the Merck and Schering-Plough organizations and subsequently led operations in 30 EU markets. Previous positions at Merck include President of Merck Canada, and vice-president of Asia Pacific where Ms. Svoronos worked extensively in Japan, mainland China and several countries in southeast Asia, building or strengthening the Merck presence in these areas. Earlier, as vice-president of global marketing for Merck’s Arthritis, Analgesics and Osteoporosis franchises, Ms. Svoronos managed the global brand positioning, market and competitive intelligence, pricing and lifecycle strategies for 10 products across these three therapeutic areas. Currently, Ms. Svoronos sits on the boards of several public companies including Endocyte and PTC Therapeutics. She received a B.A. in English and French literature from Carleton University in Ottawa, Canada.
*About Voxelotor in Sickle Cell Disease*
Voxelotor (previously called GBT440) is being developed as an oral, once-daily therapy for patients with sickle cell disease (SCD). Voxelotor works by increasing hemoglobin's affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, GBT believes voxelotor blocks polymerization and the resultant sickling of red blood cells. With the potential to improve hemolytic anemia and oxygen delivery, GBT believes that voxelotor may potentially modify the course of SCD. In recognition of the critical need for new SCD treatments, the U.S. Food and Drug Administration (FDA) has granted voxelotor Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations for the treatment of patients with SCD. The European Medicines Agency (EMA) has included voxelotor in its Priority Medicines (PRIME) program, and the European Commission (EC) has designated voxelotor as an orphan medicinal product for the treatment of patients with SCD.
GBT is currently evaluating voxelotor in the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study, a Phase 3 clinical study in patients age 12 and older with SCD. Additionally, voxelotor is being studied in the ongoing Phase 2a HOPE-KIDS 1 Study, an open-label, single- and multiple-dose study in pediatric patients (age 4 to 17) with SCD. The HOPE-KIDS 1 Study is assessing the safety, tolerability, pharmacokinetics and exploratory treatment effect of voxelotor.
*About GBT*
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing two therapies for the potential treatment of sickle cell disease, including its late-stage product candidate, voxelotor, as an oral, once-daily therapy. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
*Forward-Looking Statements *
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about GBT’s anticipated public offering, anticipated use of proceeds and other statements containing the words “anticipate,” “planned,” “believe,” “forecast,” “estimated,” “expected,” and “intend,” among others. These forward-looking statements are based on GBT’s current expectations and actual results could differ materially. Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements, including statements regarding the availability of, and sufficiency of our data to support, accelerated regulatory approval, our plans to submit an NDA for voxelotor and prepare for commercial launch, our clarity with the FDA regarding our regulatory strategy, the therapeutic potential and safety profile of voxelotor, including the potential for voxelotor to be a disease-modifying treatment for SCD, our ability to implement and complete our clinical development plans for voxelotor, our ability to engage in continued discussions with the FDA and the outcome of our discussions with the FDA, our ability to generate and report data from our ongoing and potential future studies of voxelotor (including additional data from patients enrolled in our ongoing Phase 3 HOPE Study, and data in our ongoing Phase 2a HOPE-KIDS 1 Study), regulatory review and actions relating to voxelotor, and the timing of these events, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the risks that our clinical and preclinical development activities may be delayed or terminated for a variety of reasons, that results of clinical trials may be subject to differing interpretations, that regulatory authorities may disagree with our clinical development plans or require additional studies or data to support further clinical investigation of our product candidates, that drug-related adverse events may be observed in clinical development, and that data and results may not meet regulatory requirements or otherwise be sufficient for further development, regulatory review or approval, along with those risks set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
*Contact Information: *
Myesha Lacy (investors)
GBT
650-351-4730
investor@gbt.com
Stephanie Yao (media)
GBT
650-741-7730
media@gbt.com Reported by GlobeNewswire 5 minutes ago.
↧
Robert Dawes: Drugs 'kingpin' jailed for 22 years
Robert Dawes, originally from Nottinghamshire, brokered deals with gangs in South America and Europe.
Reported by BBC News 8 minutes ago.
↧
Robert Dawes: Drug 'kingpin' jailed for 22 years
Robert Dawes, originally from Nottinghamshire, brokered deals with gangs in South America and Europe.
Reported by BBC News 10 minutes ago.
↧
Take That cancels world tour plans due to family illness
The band will now only be performing at venues in Europe
Reported by Hull Daily Mail 18 hours ago.
↧
↧
Gary Barlow CANCELS plans for Take That's 30th anniversary world tour due to 'family illness'
The 90s boyband had plans to tour all over the globe to mark their 30th anniversary, but will now stick to dates in the UK and Europe to ensure Gary can be close to home following a 'family illness'.
Reported by MailOnline 15 hours ago.
↧
Sarri: Loftus-Cheek can become a star at Chelsea
Chelsea head coach Maurizio Sarri backed midfielder Ruben Loftus-Cheek to develop into a “great player” at the club. Loftus-Cheek, 22, has only made one Premier League start this season, while he has been given more of a chance in Europe. The England international is up to six goals this campaign, with three of those coming […]
The post Sarri: Loftus-Cheek can become a star at Chelsea appeared first on Soccer News. Reported by SoccerNews.com 13 hours ago.
The post Sarri: Loftus-Cheek can become a star at Chelsea appeared first on Soccer News. Reported by SoccerNews.com 13 hours ago.
↧
Transfer news LIVE: Chelsea Hazard swap, Ozil sent Arsenal message, Liverpool, Man Utd
TRANSFER NEWS LIVE: Updates from Manchester United, Liverpool Chelsea and Arsenal and the biggest deals, gossip and rumours from across Europe.
Reported by Daily Star 8 hours ago.
↧
Lionel Messi is averaging his best-ever goals-and-assists ratio at 31
KIERAN GILL - THE NUMBERS GAME: Most goals in Europe's big five leagues: Messi, 14. Most assists: Messi, 10. Only Dimitri Payet has created more chances.
Reported by MailOnline 7 hours ago.
↧
↧
Gary Barlow CANCELS Take That 30th anniversary world tour plans after unexpected family illness
Gary Barlow has cancelled Take That's plans for a world tour [Film Magic] Gary Barlow has cancelled Take That’s 30th anniversary world tour plans after due to a family illness. Just weeks after Robbie Williams confirmed he would join the rest of them on the huge tour, Gary has revealed they will no longer be heading beyond Europe. Speaking to The Mirror, the former X Factor judge said: “We had a big ambition next year to do a world tour, but I have actually got an illness in my ...
Reported by OK! 7 hours ago.
↧
Transfer news LIVE: Latest deals in the Premier League and Europe
The January transfer window opens in less than two weeks and clubs are finalising their plans to bring in reinforcements this winter. Follow all the latest developments here.
Reported by MailOnline 7 hours ago.
↧
Tottenham target £18million rated Marseille midfield star
Tottenham Hotspur are interested in Marseille midfielder Morgan Sanson, according to Europe Mercato. The 24-year-old has established himself as a key member of the Ligue 1 side’s squad since his switch from Montpellier in 2015. However, after the club’s poor start to the season, which sees them sixth in the table and out of Europe, it […]
Reported by Shoot 6 hours ago.
↧
David Lidington warns there could be a mass cull of sheep if Britain leaves with no deal
Ex-Europe Minister and Remain supporter Mr Lidington – the Prime Minister’s de facto number two – gave a ‘chilling warning’ about the impact of No Deal.
Reported by MailOnline 30 minutes ago.
↧
↧
U.S.'s Mideast Pullout, Mattis Exit Alarm Europeans
President Trump’s unilateral decision to remove U.S. troops from Syria and Afghanistan combined with Secretary of Defense Jim Mattis’s planned departure have sparked unease across Europe and fresh calls for greater strategic independence from Washington.
Reported by Wall Street Journal 4 hours ago.
↧
Ann Budge backs Hearts youth academy to become gold mine as Jambos lead Europe in bringing talent through
The owner has high hopes for the future of the Tynecastle club with so many talented teens on the books.
Reported by Daily Record 4 hours ago.
↧
A workers' union skewered Amazon's labour practices with a whack-a-mole game about working at a warehouse over Christmas
· A British union has highlighted working conditions at Amazon warehouses over Christmas with a satirical whack-a-mole-style game.· The game was created by the GMB union, one of the biggest workers' unions in the UK.
· The game makes the player furiously click on packages while showing pop-up messages which refer to damning media and GMB reports about Amazon's working practices.
· Amazon responded that if people want to find out what it's like to work in its warehouses they are welcome to take a tour, rather than play a "fictitious computer game."
British workers' union the GMB has laid into Amazon's working practices at Christmas with a satirical online game resembling "whack-a-mole."
The game asks players to click on packages as they pop up, which gradually become impossibly fast to keep up with. You can play "Workers not Robots" yourself by clicking here.
Occasionally messages flash up such as "Time for a toilet break — actually... here's a bottle, no time for proper breaks here." This is a reference to a report from an undercover UK journalist James Bloodworth who claims he found a bottle of urine while working inside an Amazon warehouse. Amazon has disputed Bloodworth's reporting as false.
*Read more:* Amazon warehouse workers were fired via text last Christmas, anonymous staffer claims
The game takes particular aim at CEO and world's richest man Jeff Bezos. At one point a caricatured image of him pops up demanding that the player "pick faster!"
Finally the player is informed that they have been carted off in an ambulance. This is a reference to a report published by the GMB in May, after an FOI request to ambulance services in the UK revealed that over the past three years 600 ambulances were called out to 14 Amazon warehouses.
The GMB compared emergency callouts between a single Amazon warehouse in Rugeley, near Birmingham, with a similarly sized and staffed supermarket distribution center nearby. There were 115 ambulance callouts to the Amazon warehouse, compared to eight for the supermarket.
As a coda the game asks the player to "show Bezos" by sharing the website with friends and, if they purchase anything from Amazon, to leave product reviews asking Bezos to recognise the GMB.
The union has been a frequent critic of Amazon's working conditions. It has organised multiple protests of Amazon warehouses, including protests that coincided with warehouse worker strikes across Europe on Black Friday.
In response to the game, an Amazon spokeswoman said:
"We love an app as much as the next lot — but the only robots in our buildings are the ones helping our well paid, highly appreciated associates deliver for customers. If you want to see what it is really like to work inside our fulfilment centres you don't need to download a fictitious computer game — come take a tour."
Do you work at Amazon? Got a tip? Contact this reporter via email at ihamilton@businessinsider.com. You can also contact Business Insider securely via SecureDrop.
*SEE ALSO: Amazon was at the center of political feuds this year, on everything from employee pay to HQ2*
Join the conversation about this story »
NOW WATCH: USB-C was supposed to be a universal connector — but it still has a lot of problems Reported by Business Insider 2 hours ago.
↧
China’s Huawei faces new setbacks in Europe’s telecom market
LONDON (AP) — The U.S. dispute with China over a ban on tech giant Huawei is spilling over to Europe, the company’s biggest foreign market, where some countries are also starting to shun its network systems over data security concerns. Some European governments and telecom companies are following the U.S.’s lead in questioning whether using […]
Reported by Seattle Times 14 minutes ago.
↧
↧
China's Huawei faces new setbacks in Europe's telecom market
LONDON (AP) — The U.S. dispute with China over a ban on tech giant Huawei is spilling over to Europe, the company's biggest foreign market, where some countries are also starting to shun its network systems over data security concerns. Some European governments and telecom companies are following the U.S.'s lead in questioning whether using Huawei for vital infrastructure for mobile networks could leave them exposed to snooping by the Chinese government. Bans in Europe could significantly increase the financial pressures on Huawei.
Reported by SeattlePI.com 4 minutes ago.
↧
Charts of the Year: retailers and semiconductors are most shorted sectors in Europe
Reported by FT.com 2 days ago.
↧
Manchester United to splash out on defence, West Ham line up Chilean star and Liverpool chase German hot-shot
The latest round up of stories from across Europe ahead of the January transfer window
Reported by Tiverton Mid Devon Gazette 2 days ago.
↧
